Circulating cytokines in Alzheimer's disease

doi:10.1016/S0022-3956(97)00023-X

Journal of Psychiatric Research

Volume 31, Issue 6, November–December 1997, Pages 657-660

https://doi.org/10.1016/S0022-3956(97)00023-X Get rights and content

Summary

Immune factors may be involved in the pathophysiology of Alzheimer's disease (AD), a neurodegenerative disease. Since immune activation precedes immune-mediated processes, we measured plasma levels of four selective cytokines: interleukin-6 (IL-6), interleukin-12 (IL-12), interferon-alpha (IFN-α), and interferon-gamma (IFN-γ). The level of IL-6, but not other cytokines, was significantly elevated. The increase of circulating IL-6 indicates immune activation presumably related to pathophysiology of the disease.

References (15)

BauerJ. et al.
The participation of interleukin-6 in the pathogenesis of Alzheimer's disease
Research in Immunology
(1992)
FillitH. et al.
Elevated circulating tumor necrosis factor levels in Alzheimer's disease
Neuroscience Letters
(1991)
HubermanM. et al.
Correlation of cytokine secretion by mononuclear cells of Alzheimer' disease and disease stage
Journal of Neuroimmunology
(1994)
SinghV.K.
Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism
Journal of Neuroimmunology
(1996)
SinghV.K. et al.
Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children
Clinical and Immunological Immunopathology
(1991)
TrinchieriG.
Interleukin-12 and its role in the generation of TH1 cells
Immunology Today
(1993)
AragaS. et al.
Reduced natural killer cell activity in patients with dementia of the Alzheimer's type
Acta Neurologica Scandinavica
(1991)

There are more references available in the full text version of this article.

Cited by (152)

Genetics of frailty: A longevity perspective
2020, Translational Research
Frailty is a complex late life phenotype characterized by cumulative declines in multiple physiological systems that increases the risk for disability and mortality. The biological changes associated with aging are risk factors for frailty as well as for complex diseases; whereas longevity is assumed to be an outcome of protective biological mechanisms. Understanding the interplay between biological alterations associated with aging and protective mechanisms associated with longevity in the context of frailty may help guide development of interventions to increase healthspan and promote successful aging. The complexity of these phenotypes and relatively low heritability in studies are the main roadblocks in deciphering genetic mechanisms of these age associated conditions. We review genetic research related to frailty, and discuss the possible intertwined biology of frailty and longevity.
Precision pharmacology for Alzheimer's disease
2018, Pharmacological Research
The complex multifactorial nature of polygenic Alzheimer’s disease (AD) presents significant challenges for drug development. AD pathophysiology is progressing in a non-linear dynamic fashion across multiple systems levels – from molecules to organ systems – and through adaptation, to compensation, and decompensation to systems failure. Adaptation and compensation maintain homeostasis: a dynamic equilibrium resulting from the dynamic non-linear interaction between genome, epigenome, and environment. An individual vulnerability to stressors exists on the basis of individual triggers, drivers, and thresholds accounting for the initiation and failure of adaptive and compensatory responses. Consequently, the distinct pattern of AD pathophysiology in space and time must be investigated on the basis of the individual biological makeup. This requires the implementation of systems biology and neurophysiology to facilitate Precision Medicine (PM) and Precision Pharmacology (PP).
The regulation of several processes at multiple levels of complexity from gene expression to cellular cycle to tissue repair and system-wide network activation has different time delays (temporal scale) according to the affected systems (spatial scale). The initial failure might originate and occur at every level potentially affecting the whole dynamic interrelated systems within an organism. Unraveling the spatial and temporal dynamics of non-linear pathophysiological mechanisms across the continuum of hierarchical self-organized systems levels and from systems homeostasis to systems failure is key to understand AD. Measuring and, possibly, controlling space- and time-scaled adaptive and compensatory responses occurring during AD will represent a crucial step to achieve the capacity to substantially modify the disease course and progression at the best suitable timepoints, thus counteracting disrupting critical pathophysiological inputs. This approach will provide the conceptual basis for effective disease-modifying pathway-based targeted therapies.
PP is based on an exploratory and integrative strategy to complex diseases such as brain proteinopathies including AD, aimed at identifying simultaneous aberrant molecular pathways and predicting their temporal impact on the systems levels. The depiction of pathway-based molecular signatures of complex diseases contributes to the accurate and mechanistic stratification of distinct subcohorts of individuals at the earliest compensatory stage when treatment intervention may reverse, stop, or delay the disease. In addition, individualized drug selection may optimize treatment safety by decreasing risk and amplitude of side effects and adverse reactions.
From a methodological point of view, comprehensive “omics”-based biomarkers will guide the exploration of spatio-temporal systems-wide morpho-functional shifts along the continuum of AD pathophysiology, from adaptation to irreversible failure.
The Alzheimer Precision Medicine Initiative (APMI) and the APMI cohort program (APMI-CP) have commenced to facilitate a paradigm shift towards effective drug discovery and development in AD.
Visceral adiposity predicts subclinical white matter hyperintensities in middle-aged adults
2017, Obesity Research and Clinical Practice
Citation Excerpt :
Making matters worse, these adipocytokines can cross the blood–brain barrier and affect the central nervous system [39,40]. Cross-sectional studies have shown proinflammatory cytokines are elevated in individuals with obesity, and play a role in dementia related neurodegeneration [41,42]. Further, in a cross-sectional study observing the role of inflammation and cognition in an elderly sample, increased IL-6 and C reactive protein correlated to increased cognitive decline [43].
Growing prevalence of neuropathology and cognitive impairment are emerging consequences of the obesity epidemic. Adiposity indices used in examining the relationships between obesity, neuropathology, and cognition vary substantially in the literature leading to incongruent findings. Our aim was to determine the anthropometric measures most strongly associated with early white matter disease and cognitive function at midlife.
Multiple adiposity indices were measured in 126 adults aged 40–62 who also completed a magnetic resonance imaging (MRI) scan to quantify white matter disease and a cognitive test battery. Anthropometric indices of obesity were compared to image-based estimates of visceral adipose tissue with dual-energy X-ray absorptiometry (DEXA) as predictors of current white matter disease and cognitive function. We also explored sex as a potential moderator of these relationships.
Waist circumference (WC) was most strongly correlated with DEXA estimates of visceral adipose tissue (r = 0.871, p < 0.001). Increasing WC (β = 0.231, p = 0.034), percent body fat (β = 0.230, p = 0.045), and VAT (β = 0.247, p = 0.027) significantly predicted subclinical white matter hyperintensities in the absence of cognitive impairment after accounting for age, sex, years of education, and cardiovascular risk factors. Sex was not a significant moderator of any of the observed relationships.
Of the anthropometric indices used in this study, WC, BF, and VAT successfully predicted subclinical white matter disease in cognitively normal adults at midlife. Increasing VAT may independently insidiously affect cerebral white matter prior to detectable cognitive changes, necessitating early intervention.
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease
2016, Experimental Gerontology
Citation Excerpt :
In a prospective cohort study of patients with mild to severe AD, high baseline levels of TNF-α were associated with an increase in the rate of cognitive decline (Holmes et al., 2009). In addition, increased peripheral levels of IL-6 have been reported in patients with AD in various studies (Singh and Guthikonda, 1997; Licastro et al., 2000). However, in a longitudinal study with a small sample, no significant differences were observed between AD subjects and controls with respect to the mean serum levels of IL-1β, IL-1 receptor antagonist, IL-6, TNF-α, the soluble TNF receptors types I and II, and alpha 1-antichymotrypsin (Lanzrein et al., 1998).
Lipoprotein-associated phospholipase A2 (Lp-PLA₂) is a reported risk factor for dementia. However, the relationship between Alzheimer's disease (AD) and Lp-PLA₂ is still debatable and, to the best of our knowledge, no study has evaluated the associations between levels of Lp-PLA₂, proinflammatory cytokines, and neopterin in AD.
In total, 59 patients with AD and 38 non-demented individuals were included in the case–control study. Fasting serum concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), neopterin, and Lp-PLA₂ were determined using ELISA. The associations between AD and each of the variables were analyzed by logistic regression.
The median Lp-PLA₂ levels in AD and controls were similar (P = 0.29, not significant). Median serum neopterin and IL-6 levels were significantly higher in patients with AD than in controls (P = 0.0001 and P = 0.03, respectively). In regression analyses, median neopterin levels, a lower level of education, and female gender were significantly associated with AD when compared with controls (OR, 31.44, 95% CI 3.59–275.28, P = 0.002; OR, 4.35, 95% CI 1.13–16.61, P = 0.032; OR, 7.25, 95% CI 1.88–28.00, P = 0.004, respectively).
In contrast to previous evidence suggesting its role in dementia and AD, Lp-PLA₂ enzyme levels were higher in the controls, and no relationship between Lp-PLA₂ and either proinflammatory cytokines or neopterin was identified in AD. Elevated neopterin levels may be considered inflammatory markers of AD.
Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease
2016, Neurochemistry International
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid plaques and neurofibrillary tangles, as well as microglial and astroglial activation, and, finally, leading to neuronal dysfunction and death. Current treatments for AD primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for the treatment of AD patients. This review will provide an overview of the antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of a variety of nutraceuticals including curcumin, apigenin, docosahexaenoic acid, epigallocatechin gallate, α-lipoic acid and resveratrol and their potential for AD prevention and treatment. We suggest that therapeutic use of these compounds might lead to a safe strategy to delay the onset of AD or slow down its progression. The continuing investigation of the potential of these substances is necessary as they are promising compounds to yield a possible remedy for this pervasive disease.
Multiplex analyte assays to characterize different dementias: Brain inflammatory cytokines in poststroke and other dementias
2016, Neurobiology of Aging
Both the inflammatory potential and cognitive function decline during aging. The association between the repertoire of inflammatory biomarkers and cognitive decline is unclear. Inflammatory cytokines have been reported to be increased, decreased, or unchanged in the cerebrospinal fluid and sera of subjects with dementia. We assessed 112 postmortem brains from subjects diagnosed with poststroke dementia (PSD), vascular dementia, mixed dementia, and Alzheimer's disease (AD), comparing those to poststroke nondemented (PSND) subjects and age-matched controls. We analyzed 5 brain regions including the gray and white matter from the frontal and temporal lobes for a panel of cytokine and/or chemokine analytes using multiplex-array assays. Of the 37 analytes, 14 were under or near the detection limits, 7 were close to the lowest detection level, and 16 cytokines were within the linear range of the assay. We observed widely variable concentrations of C-reactive protein (CRP) and serum amyloid A at the high end (1–150 ng/mg protein), whereas several of the interleukins (IL, interferon-gamma and tumor necrosis factor) at the low end (1–10 pg/mg). There were also regional variations; most notable being high concentrations of some cytokines (e.g., CRP and angiogenesis panel) in the frontal white matter. Overall, we found decreased concentrations of several cytokines, including IL-1 beta (p = 0.000), IL-6 (p = 0.000), IL-7 (p = 0.000), IL-8 (p = 0.000), IL-16 (p = 0.001), interferon-inducible protein–10 (0.044), serum amyloid A (p = 0.011), and a trend in IL-1 alpha (p = 0.084) across all dementia groups compared to nondemented controls. IL-6 and IL-8 were significantly lower in dementia subjects than in nondemented subjects in every region. In particular, lower levels of IL-6 and IL-8 were notable in the PSD compared to PSND subjects. Because these 2 stroke groups had comparable degree of vascular pathology, the lower production of IL-6 and IL-8 in PSD reaffirms a possible specific involvement of immunosenescence in dementia pathogenesis. In contrast, CRP was not altered between dementia and nondementia subjects or between PSD and PSND. Our study provides evidence not only for the feasibility of tracking cytokines in postmortem brain tissue but also suggests differentially impaired inflammatory mechanisms underlying dementia including AD. There was a diminished inflammatory response, possibly reflecting immunosenescence and cerebral atrophy, in all dementias. Strategies to enhance anti-inflammatory cytokines and boost the immune system of the brain may be beneficial for preventing cognitive dysfunction, especially after stroke.

View all citing articles on Scopus

View full text

Circulating cytokines in Alzheimer's disease

Summary

Research in Immunology

Neuroscience Letters

Journal of Neuroimmunology

Journal of Neuroimmunology

Clinical and Immunological Immunopathology

Immunology Today

Reduced natural killer cell activity in patients with dementia of the Alzheimer's type

Acta Neurologica Scandinavica